EA201492148A1 - Способ лечения немелкоклеточного рака легких - Google Patents

Способ лечения немелкоклеточного рака легких

Info

Publication number
EA201492148A1
EA201492148A1 EA201492148A EA201492148A EA201492148A1 EA 201492148 A1 EA201492148 A1 EA 201492148A1 EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A EA201492148 A EA 201492148A EA 201492148 A1 EA201492148 A1 EA 201492148A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung cancer
cell lung
patient
inoperable
nucleotides
Prior art date
Application number
EA201492148A
Other languages
English (en)
Inventor
Чен Дуксин
Шоши Тесслер
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201492148A1 publication Critical patent/EA201492148A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способам лечения пациента из числа людей, пораженным неоперабельным, распространенным или метастатическим немелкоклеточным раком легких, включающим периодическое введение пациенту химиотерапии, включающей определенное количество доцетаксела; а также 640 мг антикластеринового олигонуклеотида, имеющего последовательность CAGCAGCAGAGTCTTCATCAT (SEQ ID NO:1), где этот антикластериновый олигонуклеотид на всем протяжении включает фосфотиоатный скелет, сахарные фрагменты нуклеотидов 1-4 и 18-21 модифицированы 2'-О-метоксиэтильными фрагментами, нуклеотиды 5-17 являются 2'-дезоксинуклеотидами, и нуклеотиды 1, 4 и 19 включают 5-метилцитозиновые фрагменты, за счет чего осуществляется лечение пациента из числа людей, пораженных неоперабельным, распространенным или метастатическим немелкоклеточным раком легких. Изобретение относится также к композициям и комбинациям, упаковкам лекарственных средств и их применению для лечения пациента, пораженного неоперабельным, распространенным или метастатическим немелкоклеточным раком легких.
EA201492148A 2012-05-18 2013-05-17 Способ лечения немелкоклеточного рака легких EA201492148A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
EA201492148A1 true EA201492148A1 (ru) 2015-04-30

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492148A EA201492148A1 (ru) 2012-05-18 2013-05-17 Способ лечения немелкоклеточного рака легких

Country Status (17)

Country Link
US (1) US20130310440A1 (ru)
EP (1) EP2849761A1 (ru)
JP (1) JP2015522542A (ru)
KR (1) KR20150024843A (ru)
CN (1) CN104684564A (ru)
AR (1) AR091090A1 (ru)
AU (1) AU2013262589A1 (ru)
BR (1) BR112014028787A2 (ru)
CA (1) CA2874092A1 (ru)
EA (1) EA201492148A1 (ru)
IL (1) IL235459A0 (ru)
IN (1) IN2014DN10390A (ru)
PH (1) PH12014502569A1 (ru)
SG (1) SG11201407649RA (ru)
TW (1) TW201402132A (ru)
UY (1) UY34812A (ru)
WO (1) WO2013173757A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2011143071A2 (en) 2010-05-08 2011-11-17 The Regents Of The University Of California Sem scanner sensing apparatus, system and methodology for early detection of ulcers
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
AU2018217187B2 (en) 2017-02-03 2020-01-02 Bruin Biometrics, Llc Measurement of edema
GB2600266B (en) 2017-02-03 2023-03-01 Bruin Biometrics Llc Measurement of tissue viability
KR102283395B1 (ko) 2017-02-03 2021-07-30 브루인 바이오메트릭스, 엘엘씨 당뇨병성 족부 궤양에 대한 감수성의 측정
WO2019099812A1 (en) * 2017-11-16 2019-05-23 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
CA3090395A1 (en) 2018-02-09 2019-08-15 Bruin Biometrics, Llc Detection of tissue damage
LT3861601T (lt) 2018-10-11 2024-03-12 Bruin Biometrics, Llc Prietaisas su vienkartiniu elementu
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
JP2014520081A (ja) * 2011-05-19 2014-08-21 テバ ファーマシューティカル インダストリーズ リミティド 非小細胞肺癌を処置するための方法

Also Published As

Publication number Publication date
TW201402132A (zh) 2014-01-16
PH12014502569A1 (en) 2015-01-21
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30
JP2015522542A (ja) 2015-08-06
CA2874092A1 (en) 2013-11-21
CN104684564A (zh) 2015-06-03
EP2849761A1 (en) 2015-03-25
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21
AU2013262589A1 (en) 2015-01-22
IN2014DN10390A (ru) 2015-08-14
UY34812A (es) 2013-12-31
WO2013173757A8 (en) 2015-04-30
IL235459A0 (en) 2014-12-31
KR20150024843A (ko) 2015-03-09
AR091090A1 (es) 2014-12-30

Similar Documents

Publication Publication Date Title
EA201492148A1 (ru) Способ лечения немелкоклеточного рака легких
MX2018012038A (es) Agentes de iarn modificados.
AR125906A2 (es) Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento del cáncer
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
RU2014101547A (ru) Апоптоз-индуцирующее средство
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
MX2013009191A (es) Oligonucleotidos antisentido.
EA201391725A1 (ru) Способ лечения немелкоклеточного рака легкого
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
WO2014022739A3 (en) Modified rnai agents
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201171415A1 (ru) Ингибиторы белков семейства iap
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
BR112015010396A2 (pt) terapia de combinação
BRPI0612334A2 (pt) uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
JP2014521342A5 (ru)
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
BR112013006541A2 (pt) agente preventivo ou terapêutico para fibrose